Sustained IL-1α, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus

Pediatric Diabetes

Volumn 9, Issue 1, 2008, Pages 9-16

  Rosa, Jaime S ^a,b   Flores, Rebecca L ^a   Oliver, Stacy R ^a   Pontello, Andria M ^a   Zaldivar, Frank P ^a   Galassetti, Pietro R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Cytokine; Glucose correction; Hyperglycemia; Inflammatory markers

Indexed keywords

EOTAXIN; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LONG ACTING INSULIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; DIABETIC ANGIOPATHY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INSULIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-4; INTERLEUKIN-6;

EID: 38049154864     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00243.x     Document Type: Article

References (48)

1. Cohen AJ, McGill PD, Rossetti RG, Guberski DL, Like AA. Glomerulopathy in spontaneously diabetic rat. Impact of glycemic control. Diabetes 1987: 36: 944-951.
2. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl J Med 1984: 311: 365-372.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005: 353: 2643-2653.
5. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996: 19: 257-267.
6. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000: 404: 787-790.
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996: 87: 2095-2147.
8. Kanakaraj P, Schafer PH, Cavender DE et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med 1998: 187: 2073-2079.
9. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci 2005: 109: 143-159.
10. Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med 2001: 250: 415-421.
11. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002: 106: 2067-2072.
12. Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001: 24: 956-957.
13. De Rekeneire N, Peila R, Ding J et al. Diabetes, hyperglycemia, and inflammation in older individuals: The Health, Aging and Body Composition Study. Diabetes Care 2006: 29: 1902-1908.
14. Galassetti PR, Iwanaga K, Pontello AM, Zaldivar FP, Flores RL, Larson JK. Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes. Am J Physiol Endocrinol Metab 2006: 290: E833-E839.
15. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: Pediatric dosing implications[ast]. Clin Pharmacol Ther 2006: 80: 582-596.
16. Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: Reliability, validity, and initial norms. J Youth Adolesc 1988: 17: 117-133.
17. Oliver JC, Bland LA, Oettinger CW et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 1993: 2: 115-120.
18. Kudo S, Mizuno K, Hirai Y, Shimizu T. Clearance and tissue distribution of recombinant human Interleukin 1{beta} in rats. Cancer Res 1990: 50: 5751-5755.
19. Ohnishi H, Lin KM, Chu TM. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res 1990: 50: 1107-1112.
20. Wolever TM, Chiasson JL, Csima A et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998: 21: 336-340.
21. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004: 164: 2090-2095.
22. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997: 20: 1822-1826.
23. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988: 37: 1595-1607.
24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c. Diabetes Care 2003: 26: 881-885.
25. Bate K, Jerums G. Preventing complications of diabetes. Med J Aust 2003: 179: 498-503.
26. Daneman D. Type 1 diabetes. Lancet 2006: 367: 847-858.
27. Crook M. Type 2 diabetes mellitus: A disease of the innate immune system? An update. Diabet Med 2004: 21: 203-207.
28. Wasmuth HEMD, Kunz DMD, Graf JMD et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-[alpha]. Crit Care Med 2004: 32: 1109-1114.
29. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000: 85: 967-972.
30. Galassetti PR, Iwanaga K, Crisostomo M, Zaldivar FP, Larson J, Pescatello A. Inflammatory cytokine, growth factor and counterregulatory responses to exercise in children with type 1 diabetes and healthy controls. Pediatr Diabetes 2006: 7: 16-24.
31. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991: 77: 1627-1652.
32. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005: 98: 1154-1162.
33. Winter CD, Pringle AK, Clough GF, Church MK. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain 2004: 127: 315-320.
34. Graziani G, Bordone G, Bellato V, Finazzi S, Angelini S, Badalamenti S. Role of the kidney in plasma cytokine removal in sepsis syndrome: A pilot study. J Nephrol 2006: 19: 176-182.
35. Drenth JP, Van Uum SH, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JW. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol 1995: 79: 1497-1503.
36. Mooradian A, Reed R, Meredith K. Serum levels of tumor necrosis factor and IL-1 alpha and IL-1 beta in diabetic patients. Diabetes Care 1991: 14: 63-65.
37. Gillespie KM. Type 1 diabetes: Pathogenesis and prevention. CMAJ 2006: 175: 165-170.
38. Campbell I. The obesity epidemic: Can we turn the tide? Heart 2003: 89: 22ii-24ii.
39. Opal SM, De Palo VA. Anti-inflammatory cytokines. Chest 2000: 117: 1162-1172.
40. Nemet D, Pontello AM, Rose-Gottron C, Cooper DM. Cytokines and growth factors during and after a wrestling season in adolescent boys. Med Sci Sports Exerc 2004: 36: 794-800.
41. Van Exel E, Gussekloo J, De Craen AJM, Frolich M, Bootsma-Van der Wiel A, Westendorp RGJ. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 Diabetes: The Leiden 85-Plus Study. Diabetes 2002: 51: 1088-1092.
42. Bluher M, Fasshauer M, Tonjes A. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005: 113: 534-537.
43. Stettler C, Allemann S, Juni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J 2006: 152: 27-38.
44. Pastore MR, Bazzigaluppi E, Bonfanti R et al. Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. Diabetes Care 1998: 21: 1445-1450.
45. Viardot A, Grey ST, Mackay F, Chisholm D. Potential anti-inflammatory role of insulin via the preferential polarization of effector T cells towards a T-helper 2 phenotype. Endocrinology 2007: 148: 346-53.
46. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NF{{kappa}}B and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001: 86: 450-453.
47. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van Den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003: 88: 1082-1088.
48. Aygun AD, Gungor S, Ustundag B, Gurgoze MK, Sen Y. Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children. Mediators Inflamm 2005: 3: 180-183.